The addition of VYVANSE, combined with ADDERALL XR and DAYTRANA's market share has helped Shire grow its total share of the US ADHD market to 30% at September 30, 2007 compared to 28% at September 30, 2006 (excluding ADDERALL, which was divested by Shire in Q3 2006). Shire's combined ADHD portfolio forms the leading portfolio of products in the US ADHD market.
PENTASA - Ulcerative colitis
US prescriptions of PENTASA for the three months to September 30, 2007 were up 2% compared to the same period in 2006 primarily due to a 4% increase in the US oral mesalamine prescription market, offset by a small decrease in PENTASA's average market share from 17.4% in Q3 2006 to 17.1% in Q3 2007.
Sales of PENTASA for the three months to September 30, 2007 were $43.7 million, an increase of 18% compared to the same period in 2006 (2006: $36.9 million). Sales growth is higher than prescription growth primarily due to the continued shift to the 500mg strength capsules as well as the impact of price increases in November 2006 and August 2007.
LIALDA - Ulcerative colitis
Shire launched LIALDA during March 2007. By September 30, 2007 LIALDA had reached a US market share of 6.4%. Preparations are underway for the European launch, commencing with the UK in Q4 2007. In the UK and Ireland the product will be called MEZAVANT XL and Shire plans to market the product in most other EU countries as MEZAVANT.
In Q3 2007 LIALDA's average share of the US oral mesalamine prescription market was 5.4%. LIALDA's product sales for the three months to September 30, 2007 were $16.3 million (Q2 2007: $5.0 million).<
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved